Get the Stockscreener App
80.95
0.24%
0.19
After Hours:
80.11
-0.84
-1.04%
Monopar Therapeutics Inc stock is traded at $80.95, with a volume of 209.96K.
It is up +0.24% in the last 24 hours and down -17.83% over the past month.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
See More
Previous Close:
$80.76
Open:
$80
24h Volume:
209.96K
Relative Volume:
2.80
Market Cap:
$499.46M
Revenue:
-
Net Income/Loss:
$-7.12M
P/E Ratio:
-35.20
EPS:
-2.3
Net Cash Flow:
$-6.82M
1W Performance:
-6.05%
1M Performance:
-17.83%
6M Performance:
+107.03%
1Y Performance:
+414.62%
1-Day Range:
$77.82
$83.86
1-Week Range:
$77.00
$86.16
52-Week Range:
$15.50
$105.00
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Name
Monopar Therapeutics Inc
Sector
Industry
Phone
(847) 388-0349
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
80.95 | 498.29M | 0 | -7.12M | -6.82M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Barclays | Overweight |
| Sep-09-25 | Initiated | BTIG Research | Buy |
| Sep-03-25 | Initiated | Oppenheimer | Outperform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Aug-26-25 | Resumed | H.C. Wainwright | Buy |
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-19-25 | Resumed | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Piper Sandler | Overweight |
| Oct-11-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-28-21 | Initiated | ROTH Capital | Buy |
View All
Monopar Therapeutics Inc Stock (MNPR) Latest News
Monopar Therapeutics announces pricing of $40M public offering of common stock - MSN
How Monopar Therapeutics Inc. (1IY0) stock correlates with oil marketsQuarterly Profit Review & Low Drawdown Investment Ideas - newser.com
Why Monopar Therapeutics Inc. stock attracts global investorsDip Buying & Verified Momentum Stock Watchlist - newser.com
What moving averages say about Monopar Therapeutics Inc.July 2025 EndofMonth & Risk Controlled Stock Alerts - newser.com
How Monopar Therapeutics Inc. (1IY0) stock reacts to monetary easing2025 EndofYear Setup & Technical Pattern Based Signals - newser.com
Top chart patterns to watch in Monopar Therapeutics Inc.2025 Technical Patterns & Expert Approved Momentum Ideas - newser.com
Monopar Therapeutics Inc. stock prediction for this weekMarket Activity Summary & Community Consensus Stock Picks - newser.com
Is Monopar Therapeutics Inc. stock entering bullish territoryJuly 2025 Short Interest & Technical Entry and Exit Tips - newser.com
Will Monopar Therapeutics Inc. stock deliver long term returnsTreasury Yields & Free Real-Time Volume Trigger Notifications - newser.com
Exit strategy if you’re trapped in Monopar Therapeutics Inc.July 2025 Institutional & Stepwise Swing Trade Plans - newser.com
Is Monopar Therapeutics Inc. forming a reversal patternTrade Analysis Report & Weekly Momentum Picks - newser.com
Heatmap analysis for Monopar Therapeutics Inc. and competitorsJuly 2025 Trade Ideas & AI Enhanced Execution Alerts - newser.com
Applying sector rotation models to Monopar Therapeutics Inc.2025 EndofYear Setup & Growth Focused Stock Reports - newser.com
Why Monopar Therapeutics Inc. stock remains a top recommendationJuly 2025 Analyst Calls & Weekly Chart Analysis and Trade Guides - newser.com
Is Monopar Therapeutics Inc. stock attractive for retirement portfoliosWall Street Watch & Verified Trade Idea Suggestions - newser.com
Monopar Therapeutics Inc expected to post a loss of 43 cents a shareEarnings Preview - TradingView
When is the best time to exit Monopar Therapeutics Inc.2025 Stock Rankings & Daily Momentum Trading Reports - newser.com
Has Monopar Therapeutics Inc. formed a bullish divergenceWeekly Profit Summary & Low Risk High Win Rate Picks - newser.com
Multi factor analysis applied to Monopar Therapeutics Inc.Wall Street Watch & Risk Managed Investment Signals - newser.com
Monopar Therapeutics (NASDAQ:MNPR) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Monopar Therapeutics Inc Stock (MNPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.44%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):